











## Disease Modifying Therapy Clinical Trials (Multi-site)




 <b>DRUG</b>	<p><b>DIAGNODE-3</b>  AGES 12-28  WITHIN 6 MONTHS OF DIAGNOSIS  LYMPH NODE INJECTION</p>	
 <b>DRUG</b>	<p><b>POLARIS</b>  AGES 18-45  WITHIN 120 DAYS OF DIAGNOSIS  SINGLE IV INJECTION</p>	
 <b>DRUG</b>	<p><b>FABULINUS</b>  AGES 12-35  WITHIN 3 MONTHS OF DIAGNOSIS  INFUSION FOLLOWED BY INJECTIONS</p>	
 <b>DRUG</b>	<p><b>TADPOL</b>  AGES 4-40  WITHIN 100 DAYS OF DIAGNOSIS  ORAL PILL</p>	
 <b>DRUG</b>	<p><b>CNP-103</b>  AGES 12-35  DIAGNOSED FOR LESS THAN 6  MONTHS  IV INFUSIONS</p>	

 DRUG	<p><b>Denosumab for Type 1 Diabetes</b>  FEMALES AGES 18-50  MALES AGES 21-50  DIAGNOSED FOR LESS THAN 6 YEARS  INJECTION</p>	
 DRUG	<p><b>T1D OBTAIN</b>  AGES 12-35  WITHIN 90 DAYS OF DIAGNOSIS  INJECTION</p>	
 DRUG	<p><b>βETA-PRESERVE</b>  AGES 1-25  WITHIN 8 WEEKS OF DIAGNOSIS  IV INFUSION</p>	
 DRUG	<p><b>BARICADE-DELAY</b>  AGES 1-36  STAGE 2 T1D (AT LEAST 2  AUTOANTIBODIES)  ORAL PILL  <b>NOT YET RECRUITING</b></p>	
 DRUG	<p><b>BARICADE-PRESERVE</b>  AGES 1-36  WITHIN 8 WEEKS OF DIAGNOSIS  IV INFUSION  <b>NOT YET RECRUITING</b></p>	

## Disease Modifying Therapy Clinical Trials (Single site)

 DRUG	<p><b>GLP-1Ra Impact on Metabolic Outcomes in Stage 2 T1DM While Receiving Teplizumab (GLP-TEP)</b>  AGES 12-50  STAGE 2 T1DM (2+ autoantibodies)  ORAL PILL</p>	
 DRUG	<p><b>PREBIOTICS IN PATIENTS WITH TYPE 1 DIABETES</b>  AGES 7+ (Lead Site)  AGES 7-17 (Subsites)  DIAGNOSED FOR LESS THAN 12 MONTHS  ORAL PILL  University of Calgary</p>	
 DRUG	<p><b>Cellular Therapy for Type 1 Diabetes Using Mesenchymal Stem Cells</b>  AGES 18-40  DIAGNOSED FOR LESS THAN 6 MONTHS  INFUSION  MEDICAL UNIVERSITY OF SOUTH CAROLINA</p>	
 DRUG	<p><b>An Adaptive Design of MTX228</b>  AGES 18-65  DIAGNOSED FOR AT LEAST 1 YEAR  ORAL PILL  UNIVERSITY OF ALBERTA</p>	
 DRUG	<p><b>MAS-1 Adjuvanted Antigen-specific Immunotherapeutic for Prevention and Treatment of Type 1 Diabetes</b>  AGES 18-45  DIAGNOSED FOR LESS THAN 2 YEARS  INJECTION  UNIVERSITY OF COLORADO, DENVER</p>	

## Trial Tools & Contact Information

 <b>TRIAL TOOLS</b>	<p><b>Clinical Trials Connection Tool</b> Match to a clinical trial in 60 seconds</p>	
 <b>CONTACT INFO</b>	<p><b>Clinical Trial Education Volunteers</b> Your key to participation! Connect with a local volunteer trained to answer any questions you may have.</p>	